TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically proven prostate cancer with a Gleason score available or interpretable.~* Patients must have prostate cancer deemed to be hormone refractory, by progression of measurable or evaluable disease or rising PSA.~* Patients must be \>18 years old~* Patients must have received at least one prior chemotherapy regimen \>3 weeks prior to initiation of study and patients must have recovered from the side effects of the therapy~* Patients must have an ECOG status of 0-3~* Patients must have normal organ and marrow function, determined within 14 days of registration.~* Patients must have been surgically or medically castrated. If the method of castration was LHRH agonists (leuprolide or goserelin), then the patient must be willing to continue the use of LHRH agonists.~* Patients must have a serum total testosterone level \<50 ng/dl~* If the patient has been treated with non-steroidal anti-androgens (flutamide, bicalutamide or nilutamide) or other hormonal treatment (megace or steroids), the patient must have stopped these agents at least 28 days prior to enrollment for flutamide, megace or steroids and at least 42 days prior to enrollment for bicalutamide or nilutamide; and the patients must have demonstrated progression of disease since the agents were suspended.~Exclusion Criteria:~* Patients with any condition that impairs the ability to swallow medications orally~* Patients who are unable to give informed consent~* Patients who have received ketoconazole treatment for prostate cancer in the past~* Patients with other active malignancies in the past 3 years except nonmelanoma skin cancer~* Patients may not be receiving any other investigational agents~* Patients with known hypersensitivity to ketoconazole~* Patients may not be taking certain medications, including terbinafine, astemizole, triazolam, statins (except pravastatin and fluvastatin) and acid suppressive agents (antacids, H2 blockers, PPI) while on ketoconazole, and patients on these medications must agree to discontinue these medications and consider alternative therapies.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketoconazole and Hydrocortisone (Type: EXPERIMENTAL): Ketoconazole 200mg PO TID + Hydrocortisone 20mg PO Qam, 10mg PO Qpm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dimethyl Fumarate (DMF) Observational Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~- Patients with multiple sclerosis (MS) who are newly initiating treatment with dimethyl fumarate (DMF) under routine clinical care are eligible to participate in the study.~Key Exclusion Criteria:~* Patients with previous exposure to dimethyl fumarate (DMF), Fumaderm (fumaric acid esters), or compounded fumarates.~* Patients participating in other clinical studies.~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dimethyl fumarate (DMF) (Type: None): Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Evaluation of Intranasal Nalmefene

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 55 years inclusive~* BMI ranging from 18 to 32 kg/m2, inclusive~* Adequate venous access~* Healthy subjects and non-dependent who are non dependent opioid experienced users, opioid experience defined as exposure to an opioid on at least 1 occasion prior to screening~Exclusion Criteria:~* History of clinically significant disease~* Significant trauma injury, major surgery, open biopsy within 30 days prior to screening~* Subject who has a difficult airway for intubation.~* Following an abnormal diet 4 weeks prior to screening~* Use of over-the-counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention~* Use of enzyme altering drugs 30 days before intervention~* Use of nasal products 28 days before intervention and throughout the study~* Previous or current opioid, alcohol, or other drug dependence~* Donated or received blood 30 days before intervention~* Women who are pregnant or breastfeeding at screening~* Women of childbearing potential unless surgically sterile or use effective contraception~* Current or recent upper respiratory tract infection~* Allergic to nalmefene or naloxone or known hypersensitivity reaction to plastics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Nalmefene (Type: EXPERIMENTAL): Nalmefene hydrochloride nasal spray, 3mg, 1 spray
- Intranasal Naloxone (Type: ACTIVE_COMPARATOR): Naloxone hydrochloride nasal spray, 4mg, 1 spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Long-term care facilities within 75 miles of one of the 121 cities that serve as CDC surveillance sites~Exclusion Criteria:~* Facilities that used high dose influenza vaccine in residents over age 65 in previous influenza season (2015-16)~* Facilities having fewer than 50 long-stay residents~* Hospital-based facilities~* Facilities with more than 20% of the population under age 65~* Facilities not submitting Minimum Data Set (MDS) data

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aTIV (Type: EXPERIMENTAL): NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
- TIV (Type: ACTIVE_COMPARATOR): NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥16 years.~* Previous normal PFTs available.~* Absence of extrathoracic GVH disease justifying initiation or intensification of systemic immunosuppressive therapy.~* Respiratory signs present for less than 6 months.~* AHSCT recipients who have developed moderate to severe bronchiolitis obliterans, defined by reduction of FEV1/VC below the 5th percentile of predicted normal or \< 80% of predicted, with FEV1 \< 80% of predicted and ≥ 40% of predicted, not reversible after inhalation of short-acting beta-2 agonist. AHSCT recipients with FEV1 \< 80% of predicted and ≥ 40% of predicted, not reversible after inhalation of short-acting beta-2 agonist and TLC ≥ 80% of predicted.~* Respiratory symptoms related to obstructive lung disease present for at least 6 months.~* Negative respiratory microbiology work-up.~* Informed consent signed by the patient or both parents of a minor.~Exclusion Criteria:~* Extrathoracic graft versus host reaction justifying initiation or intensification of systemic immunosuppressive therapy.~* Use of inhaled bronchodilator and/or corticosteroid therapy at the time of inclusion.~* Known intolerance to inhaled bronchodilators and/or corticosteroids and/or lactose.~* Personal or donor history of asthma.~* Active smoking~* FEV1 \< 40% of predicted normal or ≥ 80% of predicted normal or PO2 \< 50 mmHg.~* Documented respiratory tract infection.~* Pregnancy.~* Absence of effective contraception during the trial.~* Not covered by French national health insurance.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
- 2 (Type: PLACEBO_COMPARATOR): Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of OAG or OHT in each eye (OAG in one eye and OHT in the fellow eye is acceptable)~* Must be receiving treatment with a stable regimen of topical prostaglandin eyedrop for a minimum of 2 weeks prior to the Screening Visit; may be taking one additional IOP lowering eyedrop~* IOP of ≥ 18 mmHg and ≤ 27 mmHg in one eye or both eyes at Screening visit~* Following 4 week washout period, IOP ≥ 24 mmHg and \< 36 mmHg at 08:00 hour and IOP ≥ 22 mmHg and \< 36 mmHg in both eyes at 10:00, 12:00 and 16:00 hours.~Key Exclusion Criteria:~* Clinically significant ocular disease which might interfere with interpretation of the study efficacy endpoints or with safety assessments~* Pseudoexfoliation or pigment dispersion component glaucoma~* History of angle closure glaucoma, or narrow angles or with evidence of peripheral anterior synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to Screening~* Intraocular pressure ≥ 36 mmHg~* Cup/disc ratio of \> 0.8 in either eye~* Severe visual field defect or significant defect (sensitivity of ≤ 10dB) within 10 degrees of fixation in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AKB-9778 4% QD + Latanoprost (Type: EXPERIMENTAL): • AKB-9778 4% daily (AM) and placebo for ophthalmic solution daily (PM) plus latanoprost daily (PM) for 28 days
- AKB-9778 4% BID + Latanoprost (Type: EXPERIMENTAL): • AKB-9778 4% twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days
- Placebo Twice Daily + Latanoprost (Type: PLACEBO_COMPARATOR): • Placebo for AKB-9778 4% ophthalmic solution twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Autism in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females between the ages of 5 and 17 years 2 months.~* Weight of 15 kg or greater.~* DSM-IV diagnosis of Autistic Disorder.~* Inpatient or outpatient.~* Medication free for at least 2 weeks for all psychotropic medications (4 weeks for fluoxetine or depot neuroleptics).~* Anticonvulsants used for treatment of seizure disorder permitted if the dosage has been stable for 4 weeks and patient seizure free for at least 6 months.~* Clinical Global Impression Severity score of at least 4 and a)18 or greater on the Irritability Scale of the Aberrant Behavior Checklist or b) .5 total score on the Ritvo-Freeman scale.~* Mental age of at least 18 months.~* Negative pregnancy test~Exclusion Criteria:~* IQ below 18 months.~* Females with a positive pregnancy test. - Evidence of a prior adequate trial with risperidone.~* Evidence of hypersensitivity to risperidone.~* Past history of neuroleptic malignant syndrome.~* DSM-IV diagnosis of Pervasive Developmental Disorder other than Autistic Disorder.~* Significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, or unstable seizure disorder.~* Weight less than 15 kg.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Systemic sclerosis, as defined by American College of Rheumatology (1980) criteria~* Disease duration of \</= 60 months (defined as time from first non-Raynaud phenomenon manifestation)~* \>/= 15 and \</= 40 mRSS units at screening~* Active disease, as defined by protocol~* Uninvolved skin at injection sites~* Negative pregnancy test for a female subject of childbearing potential~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to and/or during study enrollment~* Rheumatic autoimmune disease other than systemic sclerosis~* Skin thickening (scleroderma) limited to areas distal to the elbows or knees at screening~* Previous treatment with tocilizumab~* History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies~* Severe cardiopulmonary disease~* Known active current or history of recurrent infections~* Use of any investigational, biologic, or immunosuppressive therapies including intra-articular or parenteral corticosteroids prior to study enrollment as specified in the protocol~* As specified in the protocol, any current or past medical condition or medical history involving but not limited to the nervous, renal, pulmonary, endocrine, and gastrointestinal organ systems determined by the Principal Investigator to pose a significant safety risk to any subject while participating in the study~* Primary or secondary immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Tocilizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 20 years or older at informed consent~* Subjects with essential hypertension, who do not receive any antihypertensive drugs or receive calcium channel blocker, angiotensin converting enzyme ACE inhibitor, or angiotensin-II receptor blockade ARB during run-in period (Sitting systolic blood pressure SBP ≥ 140 mmHg and \< 180 mmHg, Sitting diastolic blood pressure DBP ≥ 90 mmHg and \< 110 mmHg, and mean 24hr SBP ≥ 130 and DBP ≥ 80 mmHg)~Exclusion Criteria:~* Secondary hypertension or malignant hypertension~* Diabetes mellitus with albuminuria~* Serum potassium level \< 3.5 or ≥ 5.1 mEq/L (≥ 4.8 mEq/L if receive ACE inhibitor, or ARB)~* Reversed day-night life cycle including overnight workers~* estimated glomerular filtration rate eGFR \< 60 mL/min/1.73 m\^2.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-3150 (Type: EXPERIMENTAL): CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years or older in generally good health who are scheduled to have a total hysterectomy and who are willing to limit alcohol consumption~Exclusion Criteria:~* Patient is allergic to the study drug, other cyclooxygenase-2 (COX-2) inhibitors/nonsteroidal anti-inflammatory drugs (NSAIDS), ibuprofen, morphine, or oxycodone or has hypersensitivity to aspirin or other NSAIDS~* Patient has uncontrolled high blood pressure~* Patient has a history of drug and/or alcohol abuse within the last 5 years~* Patient has taken part in another investigational study within 4 weeks of the start of study~* Patient is breast-feeding~* Patient has an active ulcer or inflammatory bowel disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etoricoxib 120 mg (Type: EXPERIMENTAL): etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
- Etoricoxib 90 mg (Type: EXPERIMENTAL): etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo- 3 tablets once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Trial of a Behavioral Activation Telepsychology Intervention for People Who Inject Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Reports regular recent injection drug use (defined as injecting drugs on at least one day in the last week and injecting drugs for at least two months)~* Can identify at least one goal or area of change to address during treatment~* Has regular (at least twice weekly) access to an electronic device that can make phone or video calls and has access to the internet to complete online questionnaires~Exclusion Criteria:~* Attending or on a wait list to receive psychosocial substance use treatment~* \<5th grade reading level~* Impairment due to active psychosis~* Unable to give informed, voluntary, written consent to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- People who inject drugs (Type: EXPERIMENTAL): People who inject drugs recruited from a needle exchange program who will participate in a psychosocial intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naïve or -experienced adult male or female participants with confirmed chronic hepatitis C (CHC), genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) according to standard of care and in line with the current local label~* If RBV was co-administered with the ABBVIE REGIMEN, it had to be prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)~* Participants had to voluntarily sign and date an informed consent form prior to inclusion into the study~* Participant must not have participated or intended to participate in a concurrent interventional therapeutic trial~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Participants with HCV genotype 1 or 4 (Type: None): Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subantimicrobial Doxycycline in Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented moderate to severe facial acne~Exclusion Criteria:~* Other skin conditions on the face~* Previous antibiotic treatment for acne~* Use of antibiotics for any reason within the past month~* Use of new prescription regiment for acne within the last 3 months~* Positive pregnancy test in the clinic~* Cognitive impairments

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- 100 mg standard dose doxycycline BID (Type: ACTIVE_COMPARATOR): Oral, 12 weeks
- 20 mg sub-antimicrobial dose doxycycline BID (Type: EXPERIMENTAL): Oral, 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete